INTRODUCTION
Cerebral venous sinus thrombosis is a potential life threatening condition that requires rapid diagnosis and urgent treatment. The association between progestin only pill used for the treatment of menstrual disorders and cerebral venous thrombosis has rarely been reported in literature. [31] [32] [33] Rajput R et al. had documented a case of CVST in a young woman taking norethindrone acetate for menorrhagia who also had acquired hyperhomocysteinemia. 32 Hitendra Singh et al. had reported a case of norethisterone induced CVST presenting as subarachnoid haemorrhage in a patient of menorrhagia. 31 The influence of specific types of combined oral contraceptives on the risk of thrombotic events remains the most important safety issue for these products. Several studies showed an increased risk of venous thromboembolism (VTE) in current users of combined oral contraceptives and a decreasing risk by both time of use and decreasing oestrogen dose.
Results on the significance of the type of progestogen differed. Progestogen only products conferred no increased risk of venous thromboembolism, whether taken as low dose norethisterone pills, as desogestrel only pills or in the form of hormone releasing intrauterine devices. The relative risk of VTE from using oral contraceptives with norethisterone, levonorgestrel, desogestrel or gestodene decreased with decreasing oestrogen dose. The risk was higher with oral contraceptives containing the progestogen drospirenone, desogestrel, gestodene than those containing levonorgestrel.
CASE REPORT
A 24 year old married woman, a known case of polycystic ovary syndrome presented with two days history of headache, vomiting and one episode of right focal seizures. Her menstrual cycles were irregular with intermittent episodes of heavy bleeding since menarche. She was prescribed norethisterone 5mg thrice daily for past 50 days which she had stopped only after the onset of symptoms.
No history of previous seizure tendency, head trauma, fever, chest pain, shortness of breath, ataxia, double vision, facial asymmetry, limb weakness or sensory loss was present.
She was married for three years and diagnosed to have polycystic ovarian syndrome a year ago. The couple was trying conception since marriage. They were not under treatment for the same. No history of diabetes, hypertension, CAD -atherosclerotic disease or stroke.
On examination at the time of presentation she was conscious, alert, moving all limbs normally. Vitals were normal. Pupils were 2.5 mm, equally reacting to light, no neck stiffness, deep tendon reflexes were normal, plantar bilateral flexor. Cardio vascular, respiratory and per abdominal examinations were unremarkable.
Routine investigations like haemogram and biochemistry were within the normal range. MRI and MR venogram revealed right frontal lobe focal acute haemorrhage with perifocal oedema and small haemorrhage in left frontal lobe and dural venous thrombosis of anterosuperior segment of superior sagittal sinus. CT brain plain four days later showed area of haemorrhagic infarct in right frontoparietal region and a small area of infarct in left frontal region. Midline shift to left by 6mm and effacement of frontal horn of right lateral ventricle.
Thrombophilia profile including ANA, anti-PLP antibodies, factor V Leiden mutation were also in normal ranges. But serum homocysteine level was raised (>50mmol/L). Ultrasound confirmed polycystic ovaries.
Based upon this diagnostic work-up, we made the following diagnosis: Drug induced cerebral venous sinus thrombosis with polycystic ovarian syndrome with hyperhomocysteinemia as an additional risk factor.
Patient was treated with antioedema measures, antiepileptics, low molecular weight heparin followed by oral anticoagulants. The oedema resolved and the patient became asymptomatic. There were no further episodes of haemorrhage and seizures except for few episodes of headache and vomiting. She was discharged 18 days later with oral anticoagulants, anti-epileptics and multivitamins (Vit B 12 , Vit B 6 , Folic acid). She was also advised to avoid prothrombotic conditions and to have a planned pregnancy.
One year later on follow up, she was asymptomatic. Oral anticoagulant was stopped. MRI and MR cerebral venogram were repeated. Gliotic area in right frontal cerebral parenchyma was reported with complete recanalization of superior sagittal sinus. Patient was put on long term anti epileptics in view of scar. She was advised to continue multivitamins and to avoid thrombosis provokers. 
DISCUSSION
Cerebral venous sinus thrombosis is an uncommon but potentially fatal condition, especially in young women. Common etiologies include hypercoagulable states, dehydration, adjacent infectious processes, oral contraceptives, hormone replacement therapy, pregnancy and puerperium. 1 CVST was found to be more common in women than men; female to male ratio was 1.29:1. Uniform age distribution was found in men, while 61% of women were aged 20 -35 years.
CVST presents as severe headache (the most common symptom). Other features include nausea and vomiting, seizures, decreased level of consciousness to coma, and focal neurological deficits. 2 Diagnosis is by neuroimaging the thrombosed vessel -the gold standard is the combination of MRI brain with venogram. The mainstay of therapy is anticoagulation and other procedures of recanalisation. 3 Shortly after the introduction of the first combined contraceptive, a case of venous thrombosis associated with contraceptive use was reported. 4 Since then, many observational studies have shown that combined oral contraceptives are associated with a two fold to six fold increased risk of venous thrombosis. [5] [6] [7] [8] Despite the low incidence of venous thrombosis-about three per 10,000 woman years-among women of reproductive age, 9 the effect of combined oral contraceptives on venous thrombosis is large, owing to the fact that many women use oral contraceptives.
Because the oestrogen compound (ethinylestradiol) in combined oral contraceptives was thought to cause the increased risk in thrombosis, the dose of ethinylestradiol was lowered from 150-100µg in the earliest brands to 50µg in the 1960s and to 30-35µg and 20µg in the 1970s. [10] [11] [12] The reduced dose of ethinylestradiol in contraceptives was indeed associated with a reduction in the risk of venous thrombosis. [13] [14] [15] [16] [17] Apart from adjustments in the dose of ethinylestradiol, the progestogen compound was also changed in an effort to reduce the side effects. After the first generation progestogens (that is, norethisterone and lynestrol), new progestogens were developed. These new compounds were called second generation (that is, levonorgestrel) and third generation progestogens (that is, gestodene, desogestrel, norgestimate). 4 However, users of combined oral contraceptives with third generation progestogens have a higher risk of venous thrombosis than those using second generation progestogens. [5] [6] [7] [8] Other progestogens have been developed after the introduction of third generation progestogens -that is drospirenone (introduced in 2001). The thrombosis risk for contraceptives with drospirenone was found to be higher than for combined oral contraceptives using second generation progestogens. 9, 10 Although the risk of venous thrombosis increased with the dose of ethinylestradiol, this seemed to depend on the progestogen provided. It is unclear why the dose effect of ethinylestradiol might depend on the progestogen. A possibility is that there is a difference in inhibitory effects of the progestogen on the procoagulant effect of ethinylestradiol. Oral contraceptive use increases the levels of factors II, VII, VIII, protein C, and decreases the levels of antithrombin, tissue factor pathway inhibitor, and protein S. Clinical studies have showed that this effect on coagulation factors was more pronounced in desogestrel users than in levonorgestrel users, and limited to combined oral contraceptives. 18, 19 It should be kept in mind that all combined oral contraceptives increase the risk of venous thrombosis, which is not the case for the levonorgestrel intrauterine device. 20 However, if a woman prefers using combined oral contraceptives, only those with the lowest risk of venous thrombosis should be prescribed, such as levonorgestrel with 30µg of ethinylestradiol.
Homocysteine is a naturally occurring molecule in the body and it is required in several reactions that occur within cells. They result in the formation of cysteine and methionine, which can be further used by the body. If the pathways to either cysteine or methionine are blocked, due to genetic abnormalities of enzymes or deficiencies of cofactors (folic acid, Vit B 12 , Vit B 6 ) then homocysteine levels may rise. Other causes include chronic kidney disease, certain medications, cigarette smoking and alcoholism.
Normal levels are in the range between 5 to 15 micromoles per liter. Elevated levels are associated with atherosclerosis, tendency to excessive blood clotting in the arteries. Hyperhomocysteinemia has been shown to be related to clots in veins (deep vein thrombosis, pulmonary embolism), 21, 22 though the relationship is less strong than that of arterial thrombosis. 23, 24, 30 Mild hyperhomocysteinemia levels are seen in about 5% to 12% of the general population. Vitamin supplementation primarily with folic acid, and to a lesser degree with pyridoxine and VitB 12 is effective in reducing elevated levels of plasma homocysteine. 25, 30 However, it is noteworthy that so far there is no compelling data to support the treatment of hyperhomocysteinemia for the prevention of heart disease or treatment of known heart disease or blood clots. [26] [27] [28] [29] The daily recommended doses are 1mg of folic acid, 10mg of Vit B 6 , one half milligram of Vit B 12 .
CONCLUSION
Although venous thrombosis is usually linked to the ingestion of estrogen, rather than progestogen, this case illustrates that patients who are prescribed progestogen only pills for gynaecological disorders may develop thrombosis, especially if they have predisposing metabolic disorders.
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